חֲדָשׁוֹת

We’re thrilled to announce a milestone in our mission to treat and cure children with Progeria: In partnership with The Progeria Research Foundation, Eiger BioPharmaceuticals has submitted to the FDA the first part of its application seeking approval of the drug lonafarnib as a treatment for Progeria.

Get exciting updates on our progress over the past year, learn why we now refer to the population we serve as children – and young adults – with Progeria, check out the people, the science, and the events that got us where we are today, and SO MUCH MORE!

THANK YOU to all of our donors who helped us meet our goal. You are all ONE to make the cure POSSIBLE!

Care to join Ted on The Good Place set for lunch? You’ll even get a behind-the-scenes look at their next season and meet the rest of the cast! ENTER to win HERE.

The Progeria Research Foundation has some exciting updates we would like to share!

Letters of Intent are due Oct. 30, 2018. For information on submitting an application and the complete PRF grant program, please visit the PRF Website כָּאן.